BridgeBio Pharma, Inc.
BBIO
$45.95
$1.142.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -181.90M | -167.42M | -265.05M | -162.04M | -73.46M |
| Total Depreciation and Amortization | 1.32M | 1.28M | 1.37M | 1.54M | 1.57M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.48M | 83.07M | 55.41M | -17.92M | -99.85M |
| Change in Net Operating Assets | 19.42M | -116.17M | 12.95M | -2.14M | 246.44M |
| Cash from Operations | -80.68M | -199.24M | -195.33M | -180.57M | 74.70M |
| Capital Expenditure | -594.00K | -- | -47.00K | -137.00K | -54.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.00 | -42.00K | -98.00K |
| Other Investing Activities | -12.41M | -1.60M | -3.19M | 38.41M | 3.19M |
| Cash from Investing | -13.00M | -1.60M | -3.24M | 38.23M | 3.04M |
| Total Debt Issued | 300.00M | 575.00M | 500.00M | 0.00 | 0.00 |
| Total Debt Repaid | 0.00 | -459.00M | 0.00 | 0.00 | 0.00 |
| Issuance of Common Stock | 7.16M | 5.76M | 2.85M | 2.15M | -- |
| Repurchase of Common Stock | -2.00M | -50.05M | -1.40M | -1.44M | -2.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.12M | -11.38M | -27.51M | 0.00 | -3.73M |
| Cash from Financing | 302.04M | 60.33M | 473.93M | 707.00K | -5.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 208.36M | -140.50M | 275.37M | -141.63M | 72.01M |